

In the specification

Please replace paragraph [0017] in the specification as originally filed (paragraph [0019] as published) with:

In another aspect of the invention, a pharmaceutical composition for use in the treatment of urogenital conditions comprises an acrylic acid-based polymer, for example, ~~Carbopol~~-CARBOPOL®, National Formulary (hereon NF); propylparaben, NF; methylparaben, NF; propylene glycol, United States Pharmacopoeia (hereon USP); edetic acid (hereon EDTA), USP; the CKPV dimer, (which is also identified by the Trademark "CZEN002™"), Active Pharmaceutical Ingredient (hereon API); 2 M sodium hydroxide solution (hereon NaOH); and sterile water for injection, USP. It is contemplated that certain ingredients listed may be modified, replaced or eliminated.

Please replace paragraphs [0043] – [0045] in the specification as originally filed (paragraphs [0045] – [0049] as published) with:

In another aspect of the invention, a pharmaceutical composition for use in the treatment of urogenital conditions comprises a KPV dimer, preservative agents, a solvent, an alkalizer, ~~Carbopol~~ CARBOPOL®, and a gelatinizing agent. The composition may further comprise a chelating agent. These ingredients may be modified, replaced or eliminated. A KPV dimer is preferred over other useful alpha-MSH peptides as it has been shown to be more efficacious in treating vaginitis. See, Example XII below.

In another aspect of the invention, a pharmaceutical composition is disclosed for use in the treatment of uro-genital conditions wherein said composition comprises an acrylic acid-based polymer, for example, ~~Carbopol~~-CARBOPOL®, NF; propylparaben, NF; methylparaben, NF; propylene glycol, USP; EDTA, USP; the CKPV dimer, API; 2 M NaOH; and sterile water for injection, USP. Disclosed below is at least one embodiment of the invention presented in a 0.1% CKPV dimer batch of the composition weighing approximately 4Kg. A contemplate range of percentages of individual components of the invention are disclosed for different size quantities of the invention.

One type of acrylic acid-based polymer is ~~Carbopol~~-CARBOPOL®. ~~Carbopol~~-CARBOPOL® is a registered trademark for high molecular weight, crosslinked, acrylic acid based polymers available from Novcon Pharmaceuticals, ~~www.pharma.novconic.com/products/carbopol.asp~~. The amount of ~~Carbopol~~ CARBOPOL® for use in the disclosed composition ranges from at least about 60 to 100 g or at least about 1.5-2.5% of the composition. A preferred amount of ~~Carbopol~~-CARBOPOL® is at least about 80 g or at least about 2% of the composition. It will be apparent to those skilled in the art that other known gelling

agents may be utilized in addition to or in place of ~~Carbopol~~-CARBOPOL®, provided they are effective to form a gel.

Please replace paragraph [0058] in the specification as originally filed (paragraph [0062] as published) with:

A 4 Kg, 0.1 percent CKPV dimer gel batch of the composition preferably comprises:

Carbopol®, NF	80.0g
Propylparaben, NF	2.0g
Methylparaben, NF	6.0g
Propylene glycol, USP	400.0g
EDTA, USP	4.0g
The CKPV dimer, API	4.0g
2M NaOH Solution	Quantity sufficient to pH 4.0 + 0.1
Sterile water for injection, USP	3504g